Great breakthrough in implantable artificial kidney which is based on chip

The kidney is an amazing organ. It continues to work for 24 hours a day cleaning the blood and dealing with waste disposal. Every day, these organs which are on both sides of the spine and below the ribs, with a shape of soy and fist-size, filter 150 liters of blood and produce 12 liters of urine.

Transplantation is the best treatment of renal failure, but the demand for organs far greater than the supply. US Organ Procurement and Transplantation Network said there are more than 100,000 patients waiting for kidney transplant list, but last year, only 17,108 patients to get transplants.

Overall, the National Kidney Foundation estimates that more than 460,000 Americans suffer from end-stage renal disease, and 13 patients have died while waiting for kidney donation during the day in the United States. They say love kidney disease Medicare bill - including prescription drugs, including - - 2012 is about $ 87 billion.

Kidney specialist and assistant professor of medicine at the University of Tennessee Medical Center Nashville van Magdeburg, nephrologist William H. Fissell IV and his research team hopes to end this disastrous scenario, he said, "We are developing a biological mixing device can be simulated kidneys remove enough waste, salt and water, so that the patient no longer needs dialysis "goal is to produce a device small enough - approximately the size of the bottle size - so you can put patient. Implantable artificial kidney filters and contains a microchip living kidney cells and energy supply by the patient's own heart.

The kidneys project was started over a decade ago. In 2003, it received the first batch of financial allocations from the National Institutes of Health (NIH), the recent US National Institutes of Health (NIH) to Fissell professor and his research partner, the University of California, San Francisco longtime collaborator Shuvo Roy providing up to 4 years, up to $ 6 million in funding.

In 2012, the Food and Drug Administration (FDA) to give fast-track review of the project - one is used to promote and accelerate for the treatment of serious illness and possibly resolve not meet the medical needs of the current review of the way the drug. The team hopes to be able to carry out before the end of 2017 pilot studies of silicon filter. Professor Fissell said he had a lot of patients eager to participate, he expressed admiration for these patients. As he concluded, "My patient is definitely my hero. Again and again they came back from the jaws of death. They accepted the heavy burden of disease, because they want to survive. They are willing to bear all the risk to other patients."

Refer to this link: http://www.cusabio.com/Polyclonal-Antibody/Rabbit-anti-human-DNA-replication-licensing-factor-MCM3-polyclonal-AntibodyMCM3-11106199.html